Brokerages Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target at $4.79

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been assigned a consensus recommendation of “Hold” from the eleven research firms that are covering the company, MarketBeat reports. Eight analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $4.79.

Several brokerages have recently weighed in on MRNS. EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a report on Monday, September 23rd. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. StockNews.com assumed coverage on shares of Marinus Pharmaceuticals in a report on Tuesday. They set a “hold” rating on the stock. Finally, HC Wainwright reissued a “neutral” rating and set a $2.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ:MRNS opened at $0.32 on Tuesday. The company has a market cap of $17.87 million, a price-to-earnings ratio of -0.13 and a beta of 1.26. The firm’s 50-day simple moving average is $1.08 and its 200-day simple moving average is $1.26. Marinus Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $11.26.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC acquired a new position in Marinus Pharmaceuticals during the second quarter worth about $727,000. Vanguard Group Inc. raised its position in shares of Marinus Pharmaceuticals by 5.0% in the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after buying an additional 132,689 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Marinus Pharmaceuticals in the second quarter valued at approximately $813,000. Hussman Strategic Advisors Inc. raised its position in shares of Marinus Pharmaceuticals by 14.3% in the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 10,500 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Marinus Pharmaceuticals in the second quarter valued at approximately $206,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.